In a regulatory filing, Prelude Therapeutics (PRLD) disclosed that its CEO Krishna Vaddi bought 675K shares of common stock on March 25th in a total transaction size of $467K.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD: